The Cost-Effectiveness of Dananimab

Richard Oakley is the head of research and innovation at the Alzheimer's Society. He says Dananimab could slow down disease progression by about 30% or so. The next step will be to weigh up whether this is judged to be cost-effective, he adds. But which way do you think it's going to go? Because these drugs are not going to be cheap, are they?Oakley: They are going to be expensive. And the health economists are going to have to weigh up buying people, improve quality of life for a matter of months versus potentially doing a number of hit replacements.